316 filings
Page 3 of 16
8-K
8ekw5
11 May 23
Departure of Directors or Certain Officers
5:06pm
8-K
pr4nn91qgxndkb8jhf
11 May 23
Pivotal top-line data readout expected in mid-2023
8:30am
8-K
q72tut8u5 kx
5 May 23
Departure of Directors or Certain Officers
4:59pm
ARS
t48zfi6
28 Apr 23
Annual report to shareholders
8:38am
DEFA14A
oncts
28 Apr 23
Additional proxy soliciting materials
8:34am
8-K
xzh9tmhqtucn67i0w
25 Apr 23
Departure of Directors or Certain Officers
5:00pm
8-K
jovgzf 2c1z8y
31 Mar 23
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results
8:29am
424B5
rk4snrqzg1iuil md
6 Mar 23
Prospectus supplement for primary offering
4:25pm
8-K
rkgawfo17szz80a1
6 Mar 23
Entry into a Material Definitive Agreement
8:30am
8-K
sb4w0 pod4
3 Mar 23
Other Events
5:18pm
8-K
u8158t5i9enl
9 Feb 23
Other Events
8:29am
424B5
34v46
19 Jan 23
Prospectus supplement for primary offering
7:00am
8-K
r6qvbfj2fq6
18 Jan 23
Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
4:05pm
8-K
dxl8sxh6 obo8
5 Jan 23
Entry into a Material Definitive Agreement
8:35am
8-K
ral5wktl
14 Nov 22
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
9:12am
8-K
hui63t8 ss7ya
27 Sep 22
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
8:28am